GAG–Protein Interactions in Cell Signaling and Inflammation
Molecular recognition, ligand presentation and inflammatory signaling mechanisms
Abstract
Glycosaminoglycans (GAGs) are more than structural polysaccharides of the extracellular matrix. When displayed on proteoglycans or present as soluble chains, they interact with growth factors, chemokines, morphogens, enzymes, and cell-adhesion molecules. These interactions can affect ligand retention, movement through tissues, receptor engagement, and the localization of inflammatory signals. Heparan sulfate is especially important at cell surfaces, but other GAG families—including heparin, chondroitin sulfate, dermatan sulfate, and hyaluronan—provide distinct biochemical contexts. This mechanistic review examines how electrostatics, saccharide architecture, multivalency, and cellular presentation govern GAG–protein interactions, and explains experimental strategies that connect measured binding to meaningful biological function.
GAG–protein interactions, heparan sulfate binding, growth factor signaling, chemokine immobilization, inflammatory microenvironment, GAG affinity measurement, glycosaminoglycans (GAGs)
1. Introduction to GAG–Protein Interactions
GAGs are long, usually unbranched polysaccharides whose repeating disaccharides generate chemically and spatially heterogeneous surfaces. Sulfated GAGs carry negatively charged sulfate groups as well as, in most families, uronic-acid carboxylates. At physiological pH, these charged groups can engage basic patches on proteins; additional hydrogen bonds, van der Waals contacts, chain conformations, and solvent effects may increase or restrict binding. It is therefore misleading to view every GAG–protein interaction as purely nonspecific attraction between opposite charges [1–3].
Most heparan sulfate (HS) in tissues is covalently linked to core proteins as heparan sulfate proteoglycans (HSPGs). Cell-surface syndecans and glypicans, together with matrix-associated proteoglycans such as perlecan and agrin, position HS chains close to receptors and soluble ligands. This positioning can produce a locally concentrated ligand pool, establish tissue gradients, and influence the lifetime of ligand–receptor contacts [1,2].
Other GAG families offer distinct environments. Highly sulfated heparin is widely used as an experimental affinity ligand and competitor, but it is not an exact substitute for physiological HS. Chondroitin sulfate (CS) and dermatan sulfate (DS) have alternative sugar compositions and sulfation motifs. Hyaluronan lacks physiological sulfation and is not normally covalently attached to a proteoglycan core, yet it can organize pericellular matrices and interact with receptors such as CD44. Research-grade GAG materials should therefore be selected according to the biological question rather than by total negative charge alone.
Binding is not the same as signaling. A strong interaction measured with soluble heparin in vitro does not establish that the same protein is regulated by cell-surface HS, nor whether the interaction activates, inhibits, or simply localizes a ligand.
2. Molecular Determinants of GAG Binding
2.1 Sulfation sequence and local chemistry
Basic amino acids, particularly lysine and arginine, frequently contribute to GAG-binding interfaces. On the GAG side, the number and arrangement of N-sulfate, O-sulfate, and carboxylate groups create distinct electrostatic landscapes. HS includes relatively modified and less-modified domains that can support different protein contacts; local sulfate position and uronic-acid epimerization can be important even when bulk sulfate content is similar [2,3].
Specificity spans a continuum. Some proteins bind many sulfated polymers with limited sequence preference, whereas others depend on restricted motifs. The antithrombin-binding pentasaccharide sequence within certain heparin/HS chains is a classic example of a highly selective recognition event. It should not be generalized to growth factors or chemokines, whose binding often depends on combinations of sulfate distribution, domain length and protein oligomerization [2,3].
2.2 Chain length, flexibility and multivalency
A longer chain can contact multiple sites on one protein, bridge neighboring protein molecules, or present several ligands simultaneously. This multivalency can produce avidity effects and apparent binding strengths that differ from those of isolated oligosaccharides. Iduronic-acid-rich regions may adopt multiple conformations, adding another variable to recognition. Consequently, molecular weight and polydispersity must be reported alongside composition when comparing GAG preparations.
2.3 Presentation and local context
Binding measured in a solution assay may differ from binding at an endothelial glycocalyx or within collagen-rich extracellular matrix. Chain density, anchoring, neighboring proteoglycans, ionic strength, pH, and the abundance of competing proteins all change the effective accessibility of interaction sites. Glycocalyx shedding, heparanase-mediated cleavage, and matrix remodeling can redistribute bound ligands without necessarily changing the intrinsic affinity of an isolated GAG–protein pair [1,4].
| Binding determinant | Primary influence | Experimental consideration |
|---|---|---|
| Sulfation position and domain arrangement | Local recognition motifs and charge distribution | Compare matched oligosaccharides, not only total sulfate |
| Chain length and dispersity | Multivalent binding and bridging | Specify molecular-weight distribution |
| Uronic-acid epimerization | Chain flexibility and spatial presentation | Characterize GlcA/IdoA where relevant |
| Protein oligomerization | Apparent affinity and complex stoichiometry | Check concentration-dependent assemblies |
| Surface density and orientation | Accessibility, rebinding and avidity | Validate immobilized measurements in solution |
| Salt, pH and competing ligands | Electrostatic screening and competition | Use controlled buffer and matrix conditions |
Figure 1. Conceptual model of GAG–protein recognition: sulfated domains and membrane presentation can affect ligand retention, multivalent contacts and receptor engagement.
3. GAG Interactions with Growth Factors
Heparan sulfate plays well-established roles in controlling growth factor distribution and signaling. It can bind a ligand, influence its access to receptors, and sometimes contribute directly to the assembly or stabilization of an active receptor complex. These activities are particularly important where ligand concentration is low and tissue-level presentation, rather than simple diffusion, determines the cellular response [1,4].
3.1 FGF–FGFR signaling
The fibroblast growth factor (FGF) system is a model for HS-dependent signaling. For many paracrine FGFs, appropriate HS sequences contribute to the formation or stability of FGF–FGF receptor assemblies, affecting downstream pathways such as MAPK/ERK. The required HS features differ across ligands and receptor isoforms. A heparin preparation may enhance some FGF assays because of strong ligand binding, but the magnitude and direction of the effect cannot be assumed for native HS in every cell type [2,4].
3.2 Other growth factor systems
HS-binding interactions also influence other growth factor systems, including selected VEGF isoforms and PDGF family members. GAGs can determine whether a ligand remains matrix-associated, is available to a cell-surface receptor, or is released during tissue remodeling. The mechanism may be co-receptor assistance, ligand protection from degradation, sequestration, or altered diffusion; these possibilities must be distinguished experimentally.
Growth factor biology further depends on core protein identity and cell state. A syndecan-associated HS chain at the plasma membrane and a perlecan-associated chain in basement membrane do not necessarily produce equivalent signaling outcomes. For experimental interpretation, track ligand concentration, receptor abundance, growth factor isoform, and whether GAG is soluble or surface-presented.
| Protein system | Possible GAG-related role | Useful endpoint | Key caution |
|---|---|---|---|
| FGF–FGFR | Coassembly and stabilization of signaling complexes | Receptor phosphorylation, pERK, proliferation | FGF and FGFR isoforms change HS requirements |
| VEGF isoforms | Ligand retention and tissue presentation | VEGFR activation, endothelial migration | GAG binding differs among splice variants |
| Selected PDGFs | Matrix localization and ligand availability | Receptor phosphorylation, cell migration | Binding does not guarantee enhanced signaling |
| Chemokines | Immobilization and gradient organization | Directed migration and receptor signaling | Surface presentation and receptor agonism are distinct |
4. Chemokine Binding and Immune Cell Recruitment
Chemokines guide leukocyte movement by signaling through chemokine receptors, many of which are G protein-coupled receptors (GPCRs). In parallel, numerous chemokines engage GAGs on endothelial cells and extracellular matrices. These two classes of interactions serve different, though coordinated, functions: receptor binding triggers cellular signaling, whereas GAG engagement commonly governs where a chemokine is retained, presented, or transported [5,6].
4.1 Surface-bound gradients
During immune recruitment, a chemokine can be immobilized on endothelial HS, creating a surface-associated cue that migrating leukocytes encounter under blood flow. GAG binding can affect gradient steepness, duration, and protection from washout. Such patterns complement soluble concentration gradients and help explain why a chemokine with robust receptor agonism in a cell-free or static assay may behave differently in tissues [5].
4.2 Oligomerization and selectivity
Some chemokines oligomerize more readily when interacting with sulfated GAGs. Oligomerization can change matrix retention and apparent avidity, while receptor activation may preferentially involve a different state of the chemokine. However, chemokines vary markedly in their structural determinants and biological consequences of GAG binding. There is no single universal relationship between GAG affinity, oligomerization, and leukocyte recruitment [5].
For mechanistic experiments, examples such as CXCL8 and CCL5 can be useful, but effects should be tested with the relevant GAG chemistry and cell context. Competition by soluble heparin is a useful perturbation, yet it can displace many proteins and does not selectively identify a physiological HS-binding site. Parallel experiments using receptor signaling assays, defined oligosaccharides, and GAG-deficient or enzyme-treated cells support stronger mechanistic conclusions.
5. Effects on Receptor Activation and Signaling
GAG–protein interactions can facilitate, dampen, or spatially redistribute signaling. One mechanism is ligand presentation, in which a cell-surface proteoglycan increases the effective local concentration near a receptor. Another is co-receptor activity, when a GAG chain helps support a signaling-competent complex. Conversely, a soluble GAG can bind a ligand before it reaches the receptor and thereby inhibit signaling under some conditions. The net result depends on concentration, stoichiometry, chain length, and geometry [1–4].
GAGs may also contribute indirectly through receptor clustering, endocytosis, or remodeling of the matrix. In inflammatory tissues, proteoglycan shedding can transform a surface-localized signal into a more mobile pool of GAG–protein complexes. To distinguish these mechanisms, compare receptor phosphorylation or second-messenger readouts with direct ligand occupancy measurements, and include controls that preserve cell viability and receptor expression.
Increased pERK, pAKT, calcium flux, or chemotaxis after adding a sulfated GAG does not by itself demonstrate direct co-receptor action. Distinguish ligand sequestration, receptor engagement, altered matrix binding, and changes in protein stability using orthogonal assays.
Figure 2. Three context-dependent GAG mechanisms: ligand co-presentation, matrix sequestration and endothelial chemokine immobilization during immune-cell recruitment.
6. GAGs in Inflammatory Microenvironments
Inflammation alters the chemical and physical environment in which GAGs operate. Activated endothelial cells, infiltrating leukocytes, and tissue-resident stromal cells can modify proteoglycan expression and the activity of enzymes that remodel GAG-rich matrices. Such changes influence chemokine distribution, vascular permeability, leukocyte adhesion, and local growth factor availability. GAG fragments released from tissue are not necessarily functionally equivalent to the original surface-attached chains.
6.1 Glycocalyx remodeling
The endothelial glycocalyx includes HS-bearing proteoglycans and associated hyaluronan. During inflammatory injury, shedding of core-protein ectodomains and enzymatic alteration of surface glycans can change permeability and immune-cell interactions. Circulating syndecan-1 or HS fragments may be investigated as indicators of glycocalyx perturbation, but they do not provide a stand-alone quantitative measure of glycocalyx thickness or integrity.
6.2 Matrix-bound inflammatory mediators
Matrix proteoglycans can bind chemokines and other proteins and thereby shape where inflammatory signals persist. Heparanase activity may release HS fragments or associated proteins, while changes in CS/DS composition may alter stromal signaling. The resulting responses can depend on tissue, fragment size, inflammatory stimulus, and preparation purity; claims that an entire GAG family is intrinsically pro- or anti-inflammatory oversimplify the underlying mechanisms.
Mixtures such as sulodexide and glycosaminoglycan fractions may be relevant as research materials for probing vascular and inflammatory pathways, but observations with heterogeneous mixtures must not be attributed to a unique HS sequence without further fractionation and structural analysis. Similarly, anticoagulant effects of heparin or related preparations should not be conflated with unrelated receptor-signaling effects.
7. Methods for Measuring GAG–Protein Binding
A robust binding study begins with material identity. Characterize the GAG type, molecular-weight distribution, sulfation or disaccharide composition, and contaminants such as residual proteins or endotoxin when relevant. Define whether the experimental goal is equilibrium affinity, kinetic rates, binding-site mapping, competitive displacement, or a cell-level function. A single measurement rarely establishes all of these properties.
| Method | Primary readout | Strength | Important limitation |
|---|---|---|---|
| Surface plasmon resonance (SPR) | Association/dissociation kinetics and apparent affinity | Real-time, label-free measurements | Immobilization and multivalent rebinding distort simple 1:1 models |
| Biolayer interferometry (BLI) | Binding kinetics or concentration-dependent signal | Parallel, relatively accessible workflow | Surface density, avidity and transport artifacts |
| Isothermal titration calorimetry (ITC) | Heat, thermodynamics, binding stoichiometry | Solution-based, no label required | Material consumption; heterogeneous mixtures complicate models |
| Microscale thermophoresis (MST) | Concentration-dependent binding | Low sample amounts in solution-like conditions | Labeling or fluorescence artifacts and matrix effects |
| Affinity chromatography / pull-down | Retention or enrichment | Useful for discovery and relative binding | Not a stand-alone quantitative affinity measurement |
| Defined oligosaccharide arrays | Relative sequence-dependent recognition | Compares multiple motifs in parallel | Surface presentation and array composition limit inference |
| Cell-based perturbations | Receptor signaling, migration, binding localization | Biological relevance | Indirect effects and perturbation specificity require controls |
7.1 Essential experimental controls
Include a GAG-free baseline, salt-dependence series when appropriate, size- and charge-aware comparison materials, and a protein or GAG negative control. If using heparinase or heparanase treatment, confirm the biochemical scope of cleavage and avoid assuming the treatment leaves all other cell-surface properties unchanged. For cellular experiments, monitor viability, receptor abundance, and responses to ligands that are not expected to require GAG support.
Surface-based assay reports should identify which partner was immobilized, ligand density, buffer composition, regeneration conditions, and the binding model. Heterogeneous GAG chains can generate multiple binding modes; an apparent KD may be a useful operational parameter without representing one unique molecular species. Ideally, compare at least one kinetic or equilibrium assay with a functional endpoint and a chemical characterization method [2,3].
7.2 Linking binding to mechanism
Mechanistic evidence is strongest when changing one structural feature—such as a defined sulfate position or oligosaccharide length—changes direct binding and a predicted cellular response while relevant controls remain stable. Genetic disruption of HS biosynthesis, selective enzymatic remodeling, and rescue using a characterized glycan can be combined to test causal models. Interpretation should still account for the many proteins affected by a change in cell-surface GAGs.
8. Implications for Drug Discovery and Mechanistic Research
Because GAGs can regulate protein localization and receptor interactions, they are attractive research targets in inflammation, tissue repair, oncology, and vascular biology. Potential intervention strategies include defined GAG oligosaccharides, biomaterials that mimic selected binding properties, molecules that interrupt a protein's GAG-binding interface, and delivery systems that exploit matrix retention. Each approach presents different challenges in selectivity, exposure, off-target interactions, and manufacturability.
In hit discovery, high-affinity GAG binding can be a double-edged property: it may promote local retention but also increase nonspecific interactions and obscure the intended mechanism. Screening cascades should therefore include nonspecific polyanion controls, competition assays, physicochemical characterization, and orthogonal validation. An effect seen with a heparin affinity column should not be interpreted as proof of tissue-selective targeting.
For ligand- or receptor-focused studies, choose materials based on the hypothesized interaction. Defined HS oligosaccharides may be suitable for mapping FGF-related interfaces; cell-surface proteoglycan models are better suited for studying spatial presentation; and CS/DS materials may be relevant for matrix-specific questions. A heterogeneous GAG preparation is useful for exploratory screening only if conclusions remain appropriately limited.
Specify the GAG and protein identities; control chain length, sulfation and purity; distinguish soluble from immobilized presentation; measure direct binding using an appropriate model; include specificity controls; and connect binding to a defined biological endpoint before drawing mechanistic conclusions.
Ultimately, GAG–protein interactions are best understood as context-dependent molecular networks rather than a fixed catalog of high-affinity pairs. Better-defined glycan standards, structural analysis and combined biochemical/cellular experiments will help separate physiologically meaningful recognition from broad electrostatic binding. These principles also guide the responsible interpretation of sulfated glycosaminoglycans for biomedical research without implying that a given preparation has established therapeutic efficacy.
References
- Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011;3(7):a004952. doi:10.1101/cshperspect.a004952.
- Lindahl U. Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol. 2007;176(4):425–430. doi:10.1083/jcb.200608035.
- Xu D, Esko JD. Demystifying heparan sulfate-protein interactions. Annu Rev Biochem. 2014;83:129–157. doi:10.1146/annurev-biochem-060713-035314.
- Duchesne L, et al. Cytokines and growth factors cross-link heparan sulfate. Open Biol. 2015;5(8):150046. doi:10.1098/rsob.150046.
- Proudfoot AEI, Johnson Z, Bonvin P, Handel TM. Glycosaminoglycan interactions with chemokines add complexity to a complex system. Pharmaceuticals (Basel). 2017;10(3):70. doi:10.3390/ph10030070.
- Shute J. Glycosaminoglycan and chemokine/growth factor interactions. Handb Exp Pharmacol. 2012;(207):307–324. doi:10.1007/978-3-642-23056-1_13.